How is de novo lipogenesis measured?
De novo lipogenesis (DNL) is the metabolic pathway that synthesises fatty acids from non-lipid precursors such as acetyl-CoA. This page outlines the principal laboratory methods used to measure DNL flux and enzyme expres
What is de novo lipogenesis and how is it measured?
De novo lipogenesis (DNL) is the biosynthetic pathway by which acetyl-CoA is converted into fatty acids, principally palmitate, through the sequential action of acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN), and downstream elongases and desaturases. It is distinct from dietary lipid uptake and from lipolysis of stored triglyceride. In research settings, DNL is not a single analyte; it is a flux, and it is measured either as the rate at which new fatty acid molecules are produced or as the expression and activity of the enzymes that carry the pathway. The two approaches answer different questions and are not interchangeable.
The work described in the evidence below centres on the FASN arm of the pathway and on hepatic lipid handling in insulin-resistant states [1][2].
Research Studies
FASN and de novo lipogenesis in arrhythmogenic cardiomyopathy
In arrhythmogenic cardiomyopathy (ACM), a heritable disease caused by desmosomal gene mutations, FASN — described as the rate-limiting enzyme of de novo lipogenesis — was reported to be upregulated in cardiomyocytes of ACM patients and of a corresponding animal model [2]. The same work linked FASN-mediated DNL to ceramide accumulation and myocardial damage [2]. This is a disease-model finding; it does not establish that FASN measurement is a diagnostic test in general cardiology populations.
Hepatic transcriptomics and lipidomics in pre-diabetes
A registered study of diet impact on hepatic transcriptomics and lipidomics in pre-diabetes addresses non-alcoholic fatty liver disease (NAFLD), defined as excessive lipid accumulation within hepatocytes in the absence of significant alcohol consumption or other chronic liver disease causes [1]. NAFLD affects 25% to 30% of the global population and nearly one third of the population in North America [1]. Affected patients typically present with hepatic steatosis on imaging and elevated liver enzymes alongside features of insulin resistance, including pre-diabetes, type 2 diabetes mellitus, arterial hypertension, dyslipidemia, and visceral obesity [1]. The minimum histological criterion for NAFLD is greater than 5 percent steatosis [1]. DNL measurement in this context is used as one axis of lipidomic characterisation, not as a standalone diagnostic.
Direct flux measurement: stable-isotope incorporation
The reference method for DNL flux is incorporation of a stable isotope label — commonly deuterated water or 13C-acetate — into newly synthesised fatty acids, followed by mass spectrometry of the palmitate pool. This measures the fraction of a given fatty acid that was made endogenously over the labelling window. The evidence block does not supply specific isotope protocols or numerical recovery values, so no such values are stated here.
Enzyme expression and activity as a proxy for DNL
Where flux measurement is not feasible, researchers quantify FASN and ACC transcript or protein levels. The ACM work used FASN upregulation as its index of increased DNL [2]. This is an inference: higher enzyme abundance is consistent with higher pathway capacity but does not by itself demonstrate increased flux.
Comparison of DNL measurement approaches
| Approach | What it measures | Principal limitation |
|---|---|---|
| Stable-isotope incorporation | Rate of new fatty acid synthesis (flux) | Requires labelling window and mass spectrometry |
| FASN / ACC expression | Pathway enzyme abundance | Proxy only; not a flux measurement |
| Lipidomic profiling | Steady-state lipid species composition | Cannot distinguish synthesis from uptake |
Model systems in which DNL has been assessed
DNL measurement has been reported in human cardiomyocytes from ACM patients and in a corresponding animal model [2], and hepatic lipidomic and transcriptomic assessment has been proposed in pre-diabetic human populations with NAFLD [1]. Findings in cell culture and animal models should not be assumed to transfer directly to human physiology without independent confirmation.
What the evidence does not establish
The evidence block does not provide reference ranges, cut-offs, or validated clinical thresholds for DNL measurement. No claim is made here about the sensitivity or specificity of any DNL index for any disease.
If you are reading this for personal health reasons
The materials described on this page are sold for laboratory research use only. We do not provide dosing, diagnostic, or medical guidance, and nothing here should be used to self-assess or self-treat any condition. Anyone considering a compound or a measurement for their own health should speak to a licensed clinician.